لخّصلي

When heart failure (HF) worsens or is diagnosed as "de novo," or new onset HF for the first time, acute decompensation can happen suddenly and without warning. Any delay in starting treatment is linked to worse outcomes, and patients who present with acute myocardial infarction (AHF) have a dismal prognosis similar to that of those who present with AHF. In order to slow the progression of the disease and enhance prognosis, recent HF guidelines and recommendations have emphasized the significance of prompt diagnosis and therapy for individuals presenting with AHF. The ideal "time-to-treatment" impact in AHF is still unknown, nevertheless, based on the data that is now available.The 'vulnerable phase', which is marked by a high risk of readmission and early death, is also a significant factor in the clinical outcomes of HF patients following hospitalization.

When heart failure (HF) worsens or is diagnosed as "de novo," or new onset HF for the first time, acute decompensation can happen suddenly and without warning. Any delay in starting treatment is linked to worse outcomes, and patients who present with acute myocardial infarction (AHF) have a dismal prognosis similar to that of those who present with AHF. In order to slow the progression of the disease and enhance prognosis, recent HF guidelines and recommendations have emphasized the significance of prompt diagnosis and therapy for individuals presenting with AHF. The ideal "time-to-treatment" impact in AHF is still unknown, nevertheless, based on the data that is now available.
The 'vulnerable phase', which is marked by a high risk of readmission and early death, is also a significant factor in the clinical outcomes of HF patients following hospitalization. For HF patients in the "vulnerable phase," early and intense treatment may be linked to decreased odds of early readmission and death. Furthermore, when symptoms are stable in chronic stable heart failure outpatients, therapies are frequently postponed or not started, despite the possibility of unfavorable consequences including unexpected death. In order to improve their prognosis, it is imperative that HF patients be more accurately identified both during and after hospitalization and receive the proper treatment.
In all stages and illness circumstances, heart failure is a critical clinical situation. Thus, time is important for the duration of the patient's journey. Regardless of the severity or length of HF, therapy should be optimized as soon as feasible because it is advantageous. The amount of time spent prior to starting treatment is acknowledged as a significant modifiable risk factor for heart failure.